

Murray D Krahn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/400291/publications.pdf>

Version: 2024-02-01

349
papers

15,716
citations

19657

61
h-index

23533

111
g-index

355
all docs

355
docs citations

355
times ranked

19472
citing authors

#	ARTICLE	IF	CITATIONS
1	Time Costs and Out-of-Pocket Costs in Patients With Chronic Hepatitis C in a Publicly Funded Health System. <i>Value in Health</i> , 2022, 25, 247-256.	0.3	3
2	Reliability and validity of using EQ-5D-5L among healthy and adolescents with major mental health disorders in Ethiopia. <i>European Journal of Health Economics</i> , 2022, 23, 1105-1119.	2.8	10
3	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. <i>European Journal of Health Economics</i> , 2022, 23, 1309-1317.	2.8	9
4	Developing the Breast Utility Instrument, a preference-based instrument to measure health-related quality of life in women with breast cancer: Confirmatory factor analysis of the EORTC QLQ-C30 and BR45 to establish dimensions. <i>PLoS ONE</i> , 2022, 17, e0262635.	2.5	5
5	Abstract P4-12-11: Eq-5d-5l utility scores for patients with breast cancer. <i>Cancer Research</i> , 2022, 82, P4-12-11-P4-12-11.	0.9	0
6	Bring the Hoses to Where the Fire Is! Differential Impacts of Marginalization and Socioeconomic Status on COVID-19 Case Counts and Healthcare Costs. <i>Value in Health</i> , 2022, 25, 1307-1316.	0.3	4
7	No Time to Waste: An Appraisal of Value at the End of Life. <i>Value in Health</i> , 2022, 25, 1902-1909.	0.3	2
8	Pharmacological Acromegaly Treatment: Cost-Utility and Value of Information Analysis. <i>Neuroendocrinology</i> , 2021, 111, 388-402.	2.5	4
9	Treatment of Chronic Hepatitis C in Young Children Reduces Adverse Outcomes and Is Cost-Effective Compared with Deferring Treatment to Adulthood. <i>Journal of Pediatrics</i> , 2021, 230, 38-45.e2.	1.8	13
10	A Randomized Controlled Trial of an Exercise Maintenance Intervention in Men and Women After Cardiac Rehabilitation (ECO-PCR Trial). <i>Canadian Journal of Cardiology</i> , 2021, 37, 794-802.	1.7	9
11	Impact of direct-acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis c: Systematic review and meta-analysis. <i>Journal of Viral Hepatitis</i> , 2021, 28, 739-754.	2.0	23
12	Implementation, spread and impact of the Patient Oriented Discharge Summary (PODS) across Ontario hospitals: a mixed methods evaluation. <i>BMC Health Services Research</i> , 2021, 21, 361.	2.2	13
13	Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists. <i>European Journal of Health Economics</i> , 2021, 22, 723-733.	2.8	7
14	Towards Transparency in the Selection of Published Health Utility Inputs in Cost-Utility Analyses: The Health Utility Application Tool (HAT). <i>Pharmacoeconomics</i> , 2021, 39, 1075-1084.	3.3	0
15	Sex differences in direct healthcare costs following stroke: a population-based cohort study. <i>BMC Health Services Research</i> , 2021, 21, 619.	2.2	9
16	Health care costs associated with hepatitis C virus infection in First Nations populations in Ontario: a retrospective matched cohort study. <i>CMAJ Open</i> , 2021, 9, E897-E906.	2.4	5
17	Hepatitis C virus infection in First Nations populations in Ontario from 2006 to 2014: a population-based retrospective cohort analysis. <i>CMAJ Open</i> , 2021, 9, E886-E896.	2.4	2
18	Excess cost of care associated with sepsis in cancer patients: Results from a population-based case-control matched cohort. <i>PLoS ONE</i> , 2021, 16, e0255107.	2.5	4

#	ARTICLE	IF	CITATIONS
19	Association of Neighborhood-Level Material Deprivation With Health Care Costs and Outcome After Stroke. <i>Neurology</i> , 2021, 97, .	1.1	4
20	Health care costs associated with chronic hepatitis C virus infection in Ontario, Canada: a retrospective cohort study. <i>CMAJ Open</i> , 2021, 9, E167-E174.	2.4	9
21	SIESTA - Home sleep study with BresoDx for obstructive sleep apnea: a randomized controlled trial. <i>Sleep Medicine</i> , 2020, 65, 45-53.	1.6	7
22	Long-term morbidity and mortality in a Canadian post-transfusion hepatitis C cohort: Over 15 years of follow-up. <i>Journal of Viral Hepatitis</i> , 2020, 27, 235-242.	2.0	4
23	Valuing Health State: An EQ-5D-5L Value Set for Ethiopians. <i>Value in Health Regional Issues</i> , 2020, 22, 7-14.	1.2	50
24	The health impact of delaying direct-acting antiviral treatment for chronic hepatitis C: A decision-analytic approach. <i>Liver International</i> , 2020, 40, 51-59.	3.9	6
25	Picturing ELSI+: a visual representation of ethical, legal, and social issues, and patient experiences in Health Technology Assessment in Canada. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 40-49.	0.5	0
26	A Systematic Review and Meta-Analysis of Health Utilities in Patients With Chronic Hepatitis C. <i>Value in Health</i> , 2020, 23, 127-137.	0.3	24
27	Patterns of Care and Costs for Older Patients With Colorectal Cancer at the End of Life: Descriptive Study of the United States and Canada. <i>JCO Oncology Practice</i> , 2020, 16, e1-e18.	2.9	7
28	Mapping the University of Washington Quality of life questionnaire onto EQ-5D and HUI-3 indices in patients with head and neck cancer. <i>Head and Neck</i> , 2020, 42, 513-521.	2.0	10
29	Value of mesenchymal stem cell therapy for patients with septic shock: an early health economic evaluation. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 525-532.	0.5	8
30	Estimating chronic hepatitis C prevalence in British Columbia and Ontario, Canada, using population-based cohort studies. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1419-1429.	2.0	10
31	Understanding resource utilization and mortality in COPD to support policy making: A microsimulation study. <i>PLoS ONE</i> , 2020, 15, e0236559.	2.5	0
32	On the integration of early health technology assessment in the innovation process: reflections from five stakeholders. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 481-485.	0.5	12
33	Direct and indirect utilities of patients with mild to moderate versus severe carpal tunnel syndrome. <i>Journal of Hand Surgery: European Volume</i> , 2020, 45, 832-837.	1.0	2
34	Health-Related Quality of Life Changes Associated With Hearing Loss. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2020, 146, 630.	2.2	32
35	Effects of six months of aerobic and resistance training on metabolic markers and bone mineral density in older men on androgen deprivation therapy for prostate cancer. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1074-1077.	1.0	11
36	Exploring the Benefits of Transformations in Health Utility Mapping. <i>Medical Decision Making</i> , 2020, 40, 183-197.	2.4	3

#	ARTICLE	IF	CITATIONS
37	The emergency department as a setting-specific opportunity for population-based hepatitis C screening: An economic evaluation. <i>Liver International</i> , 2020, 40, 1282-1291.	3.9	19
38	Mapping the EORTC QLQ-C30 and QLQ-H&N35, onto EQ-5D-L and HUI-3 indices in patients with head and neck cancer. <i>Head and Neck</i> , 2020, 42, 2277-2286.		11
39	Comparing Childhood Cancer Care Costs in Two Canadian Provinces. <i>Healthcare Policy</i> , 2020, 15, 76-88.	0.6	2
40	Strategies to achieve population control of HCV infection: results of a multidisciplinary focus group. <i>Canadian Liver Journal</i> , 2020, 3, 224-231.	0.9	1
41	High-Cost Patients and Preventable Spending: A Population-Based Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 23-31.	4.9	10
42	Modes of coordination for health technology adoption: Health Technology Assessment agencies and Group Procurement Organizations in a polycentric regulatory regime. <i>Social Science and Medicine</i> , 2020, 265, 113528.	3.8	4
43	Resource Utilization and Costs in Adolescents Treated for Cancer in Pediatric vs Adult Institutions. <i>Journal of the National Cancer Institute</i> , 2019, 111, 322-330.	6.3	12
44	The lifetime cost of spinal cord injury in Ontario, Canada: A population-based study from the perspective of the public health care payer. <i>Journal of Spinal Cord Medicine</i> , 2019, 42, 184-193.	1.4	34
45	Health Utility Book (HUB)-Cancer: Protocol for a Systematic Literature Review of Health State Utility Values in Cancer. <i>MDM Policy and Practice</i> , 2019, 4, 238146831985259.	0.9	1
46	Using a Health Economic Framework to Prioritize Quality Indicators: An Example With Smoking Cessation in Chronic Obstructive Pulmonary Disease. <i>MDM Policy and Practice</i> , 2019, 4, 238146831985235.	0.9	0
47	Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials. <i>Systematic Reviews</i> , 2019, 8, 207.	5.3	25
48	Review of Pharmacoeconomic Studies in Russian Cancer Research: An Outside View. <i>Value in Health Regional Issues</i> , 2019, 19, 138-144.	1.2	1
49	New Insights into the Epidemiology of Prostate Cancer in Ontario. <i>Cancer Investigation</i> , 2019, 37, 513-523.	1.3	0
50	Home Dialysis is Associated with Lower Costs and Better Survival than other Modalities: A Population-Based Study in Ontario, Canada. <i>Peritoneal Dialysis International</i> , 2019, 39, 553-561.	2.3	33
51	A phase II randomized controlled trial of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy. <i>BMC Cancer</i> , 2019, 19, 2.	2.6	34
52	Estimating the clinical cost of drug development for orphan versus non-orphan drugs. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 12.	2.7	68
53	Clinical and Cost-effectiveness of a Comprehensive geriatric assessment and management for Canadian elders with Cancer—the 5C study: a study protocol for a randomised controlled phase III trial. <i>BMJ Open</i> , 2019, 9, e024485.	1.9	23
54	Toward a Centralized, Systematic Approach to the Identification, Appraisal, and Use of Health State Utility Values for Reimbursement Decision Making: Introducing the Health Utility Book (HUB). <i>Medical Decision Making</i> , 2019, 39, 371-379.	2.4	14

#	ARTICLE	IF	CITATIONS
55	Comparative effectiveness of the different components of care provided in heart failure clinicsâ€”protocol for a systematic review and network meta-analysis. <i>Systematic Reviews</i> , 2019, 8, 40.	5.3	4
56	Chlorhexidine-Related Mortality Rate in Critically Ill Subjects in Intensive Care Units: A Systematic Review and Meta-Analysis. <i>Respiratory Care</i> , 2019, 64, 337-349.	1.6	12
57	How Procurement Judges The Value of Medical Technologies: A Review of Healthcare Tenders. <i>International Journal of Technology Assessment in Health Care</i> , 2019, 35, 50-55.	0.5	26
58	Estimation of fibrosis progression rates for chronic hepatitis C: a systematic review and meta-analysis update. <i>BMJ Open</i> , 2019, 9, e027491.	1.9	23
59	Embracing the science of value in health. <i>Cmaj</i> , 2019, 191, E733-E736.	2.0	19
60	A model-based framework for chronic hepatitis C prevalence estimation. <i>PLoS ONE</i> , 2019, 14, e0225366.	2.5	5
61	The Effect of Cardiac Rehabilitation on Health-Related Quality of Life in Patients With Coronary Artery Disease: A Meta-analysis. <i>Canadian Journal of Cardiology</i> , 2019, 35, 352-364.	1.7	80
62	Quality Improvement Summit 2016: Shared Decision Making and Prostate Cancer Screening. <i>Urology Practice</i> , 2018, 5, 444-451.	0.5	4
63	Diagnostic accuracy of level IV portable sleep monitors versus polysomnography for obstructive sleep apnea: a systematic review and meta-analysis. <i>Sleep and Breathing</i> , 2018, 22, 593-611.	1.7	43
64	Gender Differences in Utilization of Specialized Heart Failure Clinics. <i>Journal of Women's Health</i> , 2018, 27, 623-629.	3.3	12
65	Lifetime cost of chronic ulcers requiring hospitalization in Ontario, Canada: A population-based study. <i>Wound Medicine</i> , 2018, 20, 21-34.	2.7	4
66	The economic burden of cancer care in Canada: a population-based cost study. <i>CMAJ Open</i> , 2018, 6, E1-E10.	2.4	79
67	Carpal Tunnel Syndrome Management in Breast Cancer Survivors at Risk for Lymphedema: A Markov Model. <i>Plastic and Reconstructive Surgery</i> , 2018, 141, 689e-696e.	1.4	4
68	The Bladder Utility Symptom Scale: A Novel Patient Reported Outcome Instrument for Bladder Cancer. <i>Journal of Urology</i> , 2018, 200, 283-291.	0.4	22
69	Changes in blood pressure among patients in the Ontario Telehomecare programme: An observational longitudinal cohort study. <i>Journal of Telemedicine and Telecare</i> , 2018, 24, 420-427.	2.7	6
70	Health Care Use and Associated Time and Out of Pocket Expenditures for Patients With Cardiovascular Disease in a Publicly Funded Health Care System. <i>Canadian Journal of Cardiology</i> , 2018, 34, 52-60.	1.7	2
71	Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures. <i>BJU International</i> , 2018, 121, 17-28.	2.5	26
72	Comparative Effectiveness of the Core Components of Cardiac Rehabilitation on Mortality and Morbidity: A Systematic Review and Network Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2018, 7, 514.	2.4	114

#	ARTICLE	IF	CITATIONS
73	Future Directions for Cost-effectiveness Analyses in Health and Medicine. <i>Medical Decision Making</i> , 2018, 38, 767-777.	2.4	58
74	Protocol for a phase III RCT and economic analysis of two exercise delivery methods in men with PC on ADT. <i>BMC Cancer</i> , 2018, 18, 1031.	2.6	3
75	Cost analysis of Greenlight photoselective vaporization of the prostate compared to transurethral resection of the prostate for benign prostatic hyperplasia. <i>Canadian Urological Association Journal</i> , 2018, 12, .	0.6	13
76	DEVELOPMENT OF THE ONTARIO DECISION FRAMEWORK: A VALUES BASED FRAMEWORK FOR HEALTH TECHNOLOGY ASSESSMENT. <i>International Journal of Technology Assessment in Health Care</i> , 2018, 34, 290-299.	0.5	22
77	Pharmacotherapy vs surgery as initial therapy for patients with moderate-to-severe benign prostate hyperplasia: a cost-effectiveness analysis. <i>BJU International</i> , 2018, 122, 879-888.	2.5	20
78	Turning High-Risk Individuals: An Economic Evaluation of Repositioning Frequency in Long-Term Care. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 1409-1414.	2.6	1
79	Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis. <i>CMAJ Open</i> , 2017, 5, E97-E108.	2.4	20
80	Costs of cancer care in children and adolescents in Ontario, Canada. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26628.	1.5	15
81	Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature. <i>Pharmacoeconomics</i> , 2017, 35, 727-740.	3.3	116
82	The characteristics of stroke units in Ontario: a pan-provincial survey. <i>BMC Health Services Research</i> , 2017, 17, 154.	2.2	3
83	Costs for Childhood and Adolescent Cancer, 90 Days Prediagnosis and 1 Year Postdiagnosis: A Population-Based Study in Ontario, Canada. <i>Value in Health</i> , 2017, 20, 345-356.	0.3	26
84	Decision making about healthcare-related tests and diagnostic test strategies. Paper 5: a qualitative study with experts suggests that test accuracy data alone is rarely sufficient for decision making. <i>Journal of Clinical Epidemiology</i> , 2017, 92, 47-57.	5.0	10
85	Model-based projection of health and economic effects of screening for hepatitis C in Canada. <i>CMAJ Open</i> , 2017, 5, E662-E672.	2.4	23
86	Canadian hepatitis C virus screening guideline: a disconnect between evidence and recommendations. <i>Cmaj</i> , 2017, 189, E1150-E1150.	2.0	2
87	Health utilities in people with chronic pain using a population-level survey and linked health care administrative data. <i>Pain</i> , 2017, 158, 408-416.	4.2	18
88	Patients' and clinicians' experiences of wound care in Canada: a descriptive qualitative study. <i>Journal of Wound Care</i> , 2017, 26, S4-S13.	1.2	55
89	Preferences of Pregnant Women and Family Members for Health States Arising From Anticoagulant Use in Pregnancy [17N]. <i>Obstetrics and Gynecology</i> , 2017, 129, S147-S147.	2.4	2
90	Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology. <i>Pharmacoeconomics - Open</i> , 2017, 1, 167-173.	1.8	4

#	ARTICLE	IF	CITATIONS
91	Review of early assessment models of innovative medical technologies. <i>Health Policy</i> , 2017, 121, 870-879.	3.0	15
92	Benefits and harms of prostate cancer screening – predictions of the ONCOTYROL prostate cancer outcome and policy model. <i>BMC Public Health</i> , 2017, 17, 596.	2.9	12
93	Effects of long-term androgen deprivation therapy on cognitive function over 36 months in men with prostate cancer. <i>Cancer</i> , 2017, 123, 237-244.	4.1	51
94	A population-based matched cohort study examining the mortality and costs of patients with community-onset <i>Clostridium difficile</i> infection identified using emergency department visits and hospital admissions. <i>PLoS ONE</i> , 2017, 12, e0172410.	2.5	22
95	Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online. <i>BMC Cancer</i> , 2017, 17, 685.	2.6	14
96	Estimating the Cost of Cancer Care in British Columbia and Ontario: A Canadian Inter-Provincial Comparison. <i>Healthcare Policy</i> , 2017, 12, 95-108.	0.6	12
97	Estimating the Cost of Cancer Care in British Columbia and Ontario: A Canadian Inter-Provincial Comparison. <i>Healthcare Policy</i> , 2017, 12, 95-108.	0.6	19
98	Systematic review and network meta-analysis of stroke-prevention treatments in patients with atrial fibrillation. <i>Clinical Pharmacology: Advances and Applications</i> , 2016, Volume 8, 93-107.	1.2	35
99	Association of hospital and physician case volumes with cardiac monitoring and cardiotoxicity during adjuvant trastuzumab treatment for breast cancer: a retrospective cohort study. <i>CMAJ Open</i> , 2016, 4, E66-E72.	2.4	10
100	Predictors of diagnostic neuroimaging delays among adults presenting with symptoms suggestive of acute stroke in Ontario: a prospective cohort study. <i>CMAJ Open</i> , 2016, 4, E331-E337.	2.4	9
101	Valuing Health Outcomes. , 2016, , 167-200.		7
102	Using Cost-Effectiveness Analysis in Health and Medicine. , 2016, , 1-38.		6
103	The Economic Burden of Hospital-Acquired <i>Clostridium difficile</i> Infection: A Population-Based Matched Cohort Study. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 1068-1078.	1.8	21
104	Disparities in a provision of in-hospital post-arrest interventions for out-of-hospital cardiac arrest (OHCA) in the elderly population – protocol for a systematic review. <i>Systematic Reviews</i> , 2016, 5, 55.	5.3	4
105	Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 535-544.	2.5	23
106	Ecologically optimizing exercise maintenance in men and women post-cardiac rehabilitation: Protocol for a randomized controlled trial of efficacy with economics (ECO-PCR). <i>Contemporary Clinical Trials</i> , 2016, 50, 116-123.	1.8	5
107	Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1093.	7.4	2,149
108	Low-Dose-Rate Brachytherapy versus. Standard Fractionated External Beam Radiotherapy versus. Stereotactic Body Radiotherapy for Low-Risk Prostate Cancer: A Cost-Utility Analysis. <i>Brachytherapy</i> , 2016, 15, S96-S97.	0.5	0

#	ARTICLE	IF	CITATIONS
109	Phase-specific and lifetime costs of cancer care in Ontario, Canada. BMC Cancer, 2016, 16, 809.	2.6	71
110	Factors affecting the delivery of community pharmacist-led medication reviews: evidence from the MedsCheck annual service in Ontario. BMC Health Services Research, 2016, 16, 666.	2.2	21
111	Reply. Pain, 2016, 157, 1834-1834.	4.2	0
112	Using Phase-Based Costing of Real-World Data to Inform Decision-Analytic Models for Atrial Fibrillation. Applied Health Economics and Health Policy, 2016, 14, 313-322.	2.1	6
113	Incremental health care costs for chronic pain in Ontario, Canada: a population-based matched cohort study of adolescents and adults using administrative data. Pain, 2016, 157, 1626-1633.	4.2	79
114	Management of neck pain and associated disorders: A clinical practice guideline from the Ontario Protocol for Traffic Injury Management (OPTIMA) Collaboration. European Spine Journal, 2016, 25, 2000-2022.	2.2	173
115	The cost-utility of integrated cervical cancer prevention strategies in the Ontario setting - Can we do better?. Vaccine, 2016, 34, 1936-1944.	3.8	7
116	Lessons Learned from a Cross-Model Validation between a Discrete Event Simulation Model and a Cohort State-Transition Model for Personalized Breast Cancer Treatment. Medical Decision Making, 2016, 36, 375-390.	2.4	6
117	Patients' Values Related to Treatment Options for Teeth with Apical Periodontitis. Journal of Endodontics, 2016, 42, 365-370.	3.1	23
118	Authors' response. Journal of the American Dental Association, 2016, 147, 6-7.	1.5	0
119	The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study. Journal of the National Cancer Institute, 2016, 108, djv301.	6.3	62
120	Recommendations on Perspectives for the Reference Case. , 2016, , 67-74.		4
121	The ONCOTYROL Prostate Cancer Outcome and Policy Model. Medical Decision Making, 2015, 35, 758-772.	2.4	8
122	Use of forecasted assessment of quality of life to validate time-trade-off utilities and a prostate cancer screening decision-analytic model. Health Expectations, 2015, 18, 1610-1620.	2.6	3
123	A multi-level qualitative analysis of Telehomecare in Ontario: challenges and opportunities. BMC Health Services Research, 2015, 15, 544.	2.2	37
124	An international comparison of costs of end-of-life care for advanced lung cancer patients using health administrative data. Palliative Medicine, 2015, 29, 918-928.	3.1	43
125	Long-term impact of androgen-deprivation therapy on physical function and quality of life. Cancer, 2015, 121, 2350-2357.	4.1	47
126	Disease burden of chronic hepatitis C among immigrants in Canada. Journal of Viral Hepatitis, 2015, 22, 1043-1054.	2.0	2

#	ARTICLE	IF	CITATIONS
127	The Opportunity Cost of Capital. <i>Inquiry (United States)</i> , 2015, 52, 004695801558464.	0.9	8
128	Performance of the disease risk score in a cohort study with policy-induced selection bias. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 607-614.	1.4	0
129	Care in the Home for the Management of Chronic Heart Failure. <i>Journal of Cardiovascular Nursing</i> , 2015, 30, S44-S51.	1.1	36
130	A phase II RCT and economic analysis of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy. <i>BMC Cancer</i> , 2015, 15, 312.	2.6	22
131	Cost-effectiveness of screening for hepatitis C in Canada. <i>Cmaj</i> , 2015, 187, E110-E121.	2.0	65
132	Economic Evaluation of Hormonal Therapies for Postmenopausal Women with Estrogen Receptor-Positive Early Breast Cancer in Canada. <i>Current Oncology</i> , 2015, 22, 84-96.	2.2	14
133	Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 639-652.	2.5	11
134	The Economic Impact of Clostridium difficile Infection: A Systematic Review. <i>American Journal of Gastroenterology</i> , 2015, 110, 511-519.	0.4	107
135	Structure and characteristics of community-based multidisciplinary wound care teams in Ontario: An environmental scan. <i>Wound Repair and Regeneration</i> , 2015, 23, 22-29.	3.0	9
136	A practical approach to evidence-based dentistry: IX. <i>Journal of the American Dental Association</i> , 2015, 146, 679-689.e1.	1.5	4
137	Predicting utility scores for prostate cancer: mapping the Prostate Cancer Index to the Patient-Oriented Prostate Utility Scale (PORPUS). <i>Prostate Cancer and Prostatic Diseases</i> , 2014, 17, 47-56.	3.9	9
138	Incorporating economic evaluation into immunization decision making in Canada: a workshop. <i>Expert Review of Vaccines</i> , 2014, 13, 1291-1296.	4.4	4
139	Prostate cancer screening: going beyond the clinical evidence. <i>Cmaj</i> , 2014, 186, 1201-1201.	2.0	11
140	Pressure ulcer multidisciplinary teams via telemedicine: a pragmatic cluster randomized stepped wedge trial in long term care. <i>BMC Health Services Research</i> , 2014, 14, 83.	2.2	62
141	Cost-effectiveness of Dalteparin vs Unfractionated Heparin for the Prevention of Venous Thromboembolism in Critically Ill Patients. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 2135.	7.4	50
142	The Effect of Multidisciplinary Heart Failure Clinic Characteristics on 1-Year Postdischarge Health Care Costs. <i>Medical Care</i> , 2014, 52, 272-279.	2.4	14
143	Health Care Costs for State Transition Models in Prostate Cancer. <i>Medical Decision Making</i> , 2014, 34, 366-378.	2.4	22
144	Identifying Future Research Priorities Using Value of Information Analyses: Left Atrial Appendage Occlusion Devices in Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2014, 3, e001031.	3.7	8

#	ARTICLE	IF	CITATIONS
145	Response to "The Life Table Method of Half-Cycle Correction: Getting It Right", Medical Decision Making, 2014, 34, 286-287.	2.4	6
146	Screening for HCV. Cmaj, 2014, 186, 294.1-294.	2.0	0
147	Patients' preferences and trade-offs for the treatment of early stage hepatocellular carcinoma. Journal of Surgical Research, 2014, 189, 57-67.	1.6	11
148	Patient time and out-of-pocket costs for long-term prostate cancer survivors in Ontario, Canada. Journal of Cancer Survivorship, 2014, 8, 9-20.	2.9	39
149	Conceptualizing global health-related quality of life in bladder cancer. Quality of Life Research, 2014, 23, 2153-2167.	3.1	16
150	Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis. Osteoporosis International, 2014, 25, 1225-1235.	3.1	44
151	Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis"reply to Pazianas and Abrahamsen. Osteoporosis International, 2014, 25, 2671-2672.	3.1	10
152	Systematic Review, Critical Appraisal, and Analysis of the Quality of Economic Evaluations in Stroke Imaging. Stroke, 2014, 45, 807-814.	2.0	3
153	Cost Effectiveness of EML4-ALK Fusion Testing and First-Line Crizotinib Treatment for Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2014, 32, 1012-1019.	1.6	85
154	Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis. BMC Cancer, 2014, 14, 586.	2.6	41
155	Early economic evaluation of emerging health technologies: protocol of a systematic review. Systematic Reviews, 2014, 3, 81.	5.3	19
156	Health-related quality of life following radical prostatectomy: long-term outcomes. Quality of Life Research, 2014, 23, 2309-2317.	3.1	22
157	Adaptation and validation of the Spanish version of the Patient-Oriented Prostate Utility Scale (PORPUS). Quality of Life Research, 2014, 23, 2481-2487.	3.1	3
158	Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada. Vaccine, 2014, 32, 5436-5446.	3.8	48
159	Clinical Decision Making for a Tooth with Apical Periodontitis: The Patients' Preferred Level of Participation. Journal of Endodontics, 2014, 40, 784-789.	3.1	21
160	Toward more specific and transparent research and development costs: The case of seasonal influenza vaccines. Vaccine, 2014, 32, 3336-3340.	3.8	15
161	Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial. Trials, 2014, 15, 502.	1.6	10
162	Turning for Ulcer Reduction (TURN) Study: An Economic Analysis. Ontario Health Technology Assessment Series, 2014, 14, 1-24.	1.8	2

#	ARTICLE	IF	CITATIONS
163	Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D. <i>Osteoporosis International</i> , 2013, 24, 2571-2579.	3.1	38
164	A reference set of health utilities for long-term survivors of prostate cancer: population-based data from Ontario, Canada. <i>Quality of Life Research</i> , 2013, 22, 2951-2962.	3.1	22
165	A Survey of Patients' Preferences for the Treatment of Teeth with Apical Periodontitis. <i>Journal of Endodontics</i> , 2013, 39, 1534-1541.	3.1	28
166	A Survey of Dentists' Preferences for the Treatment of Teeth with Apical Periodontitis. <i>Journal of Endodontics</i> , 2013, 39, 1226-1233.	3.1	25
167	Beyond case fatality rate: using potential impact fraction to estimate the effect of increasing treatment uptake on mortality. <i>BMC Medical Research Methodology</i> , 2013, 13, 109.	3.1	3
168	Direct health-care costs attributed to hip fractures among seniors: a matched cohort study. <i>Osteoporosis International</i> , 2013, 24, 659-669.	3.1	124
169	Canada's Contribution to Global Research in Cardiovascular Diseases. <i>Canadian Journal of Cardiology</i> , 2013, 29, 742-746.	1.7	3
170	Insights Into the Contemporary Management of Heart Failure in Specialized Multidisciplinary Ambulatory Clinics. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1062-1068.	1.7	12
171	Medical Therapy v. PCI in Stable Coronary Artery Disease. <i>Medical Decision Making</i> , 2013, 33, 891-905.	2.4	16
172	Cost-Effectiveness of the 21-Gene Assay for Guiding Adjuvant Chemotherapy Decisions in Early Breast Cancer. <i>Value in Health</i> , 2013, 16, 729-739.	0.3	36
173	Health care costs associated with hepatocellular carcinoma: A population-based study. <i>Hepatology</i> , 2013, 58, 1375-1384.	7.3	64
174	Understanding the costs of cancer care before and after diagnosis for the 21 most common cancers in Ontario: a population-based descriptive study. <i>CMAJ Open</i> , 2013, 1, E1-E8.	2.4	85
175	Trends in use and cost of initial cancer treatment in Ontario: a population-based descriptive study. <i>CMAJ Open</i> , 2013, 1, E151-E158.	2.4	37
176	Estimating the payoffs from cardiovascular disease research in Canada: an economic analysis. <i>CMAJ Open</i> , 2013, 1, E83-E90.	2.4	12
177	A Population-Based Study to Evaluate the Effectiveness of Multidisciplinary Heart Failure Clinics and Identify Important Service Components. <i>Circulation: Heart Failure</i> , 2013, 6, 68-75.	3.9	53
178	QUANTITATIVE PATIENT PREFERENCE EVIDENCE FOR HEALTH TECHNOLOGY ASSESSMENT: A CASE STUDY. <i>International Journal of Technology Assessment in Health Care</i> , 2013, 29, 290-300.	0.5	22
179	Comparing Cancer Care, Outcomes, and Costs Across Health Systems: Charting the Course. <i>Journal of the National Cancer Institute Monographs</i> , 2013, 2013, 124-130.	2.1	28
180	The Half-Cycle Correction Revisited. <i>Medical Decision Making</i> , 2013, 33, 961-970.	2.4	31

#	ARTICLE	IF	CITATIONS
181	Changes in health utilities and health-related quality of life over 12 months following radical prostatectomy. <i>Canadian Urological Association Journal</i> , 2013, 3, 445.	0.6	16
182	Disease Burden of Chronic Hepatitis B among Immigrants in Canada. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2013, 27, 137-147.	1.7	24
183	Cost-Utility Analysis of Primary Prophylaxis Versus Secondary Prophylaxis With Granulocyte Colony-Stimulating Factor in Elderly Patients With Diffuse Aggressive Lymphoma Receiving Curative-Intent Chemotherapy. <i>Journal of Clinical Oncology</i> , 2012, 30, 1064-1071.	1.6	30
184	Use of a Catalytic Model to Estimate Hepatitis A Incidence in a Low-Endemicity Country. <i>Medical Decision Making</i> , 2012, 32, 167-175.	2.4	5
185	The Future of Health Technology Assessment. <i>Medical Decision Making</i> , 2012, 32, 7-8.	2.4	2
186	Hepatitis B Virus Screening Before Chemotherapy for Lymphoma: A Cost-Effectiveness Analysis. <i>Journal of Clinical Oncology</i> , 2012, 30, 3167-3173.	1.6	94
187	Comparative economic analyses of patient safety improvement strategies in acute care: a systematic review. <i>BMJ Quality and Safety</i> , 2012, 21, 448-456.	3.7	51
188	The economic burden of patient safety targets in acute care: a systematic review. <i>Drug, Healthcare and Patient Safety</i> , 2012, 4, 141.	2.5	26
189	Prescribing Gabapentin off Label: Perspectives from Psychiatry, Pain and Neurology Specialists. <i>Canadian Pharmacists Journal</i> , 2012, 145, 280-284.e1.	0.8	32
190	Conceptualizing a Model. <i>Medical Decision Making</i> , 2012, 32, 678-689.	2.4	216
191	Development and Validation of a Utility Weighting Function for the Patient-Oriented Prostate Utility Scale (PORPUS). <i>Medical Decision Making</i> , 2012, 32, 11-30.	2.4	27
192	Patient time costs and out-of-pocket costs in hepatitis C. <i>Liver International</i> , 2012, 32, 815-825.	3.9	20
193	Understanding the role of scientific evidence in consumer evaluation of natural health products for osteoarthritis an application of the means end chain approach. <i>BMC Complementary and Alternative Medicine</i> , 2012, 12, 198.	3.7	9
194	Specialized multi-disciplinary heart failure clinics in Ontario, Canada: an environmental scan. <i>BMC Health Services Research</i> , 2012, 12, 236.	2.2	28
195	How much are we spending? The estimation of research expenditures on cardiovascular disease in Canada. <i>BMC Health Services Research</i> , 2012, 12, 281.	2.2	7
196	Guidelines for Health Technologies: Specific Guidance for Oncology Products in Canada. <i>Value in Health</i> , 2012, 15, 580-585.	0.3	14
197	Conceptualizing a Model: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2. <i>Value in Health</i> , 2012, 15, 804-811.	0.3	160
198	Cost Effectiveness of Hepatitis C-Related Interventions Targeting Substance Users and Other High-Risk Groups. <i>Pharmacoeconomics</i> , 2012, 30, 1015-1034.	3.3	14

#	ARTICLE	IF	CITATIONS
199	Health State Utilities and Quality of Life in Patients with Hepatitis B. Canadian Journal of Gastroenterology & Hepatology, 2012, 26, 445-451.	1.7	54
200	Techniques for estimating health care costs with censored data: an overview for the health services researcher. ClinicoEconomics and Outcomes Research, 2012, 4, 145.	1.9	49
201	Economic analysis of Heart and Stroke Foundation of Ontario's Hypertension Management Initiative. ClinicoEconomics and Outcomes Research, 2012, 4, 323.	1.9	2
202	Health utilities and psychometric quality of life in patients with early and late stage hepatitis C virus infection. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 149-157.	2.8	61
203	Impact of rituximab on treatment outcomes of patients with diffuse large cell lymphoma: a population-based analysis. British Journal of Haematology, 2012, 158, 481-488.	2.5	37
204	Immigrant patients with chronic hepatitis C and advanced fibrosis have a higher risk of hepatocellular carcinoma. Journal of Viral Hepatitis, 2012, 19, 574-580.	2.0	15
205	Influence of Socioeconomic Status on Survival of Hepatocellular Carcinoma in the Ontario Population; A Population-Based Study, 1990-2009. PLoS ONE, 2012, 7, e40917.	2.5	36
206	Health Economic and Infectious Disease Modelling. Pharmacoeconomics, 2011, 29, 367-369.	3.3	2
207	Predictors of Family Caregiver Ratings of Patient Quality of Life in Alzheimer Disease: Cross-Sectional Results from the Canadian Alzheimer's Disease Quality of Life Study. American Journal of Geriatric Psychiatry, 2011, 19, 891-901.	1.2	43
208	Predictors of Patient Self-Ratings of Quality of Life in Alzheimer Disease: Cross-Sectional Results From the Canadian Alzheimer's Disease Quality of Life Study. American Journal of Geriatric Psychiatry, 2011, 19, 881-890.	1.2	46
209	Achieving Quality Indicator Benchmarks and Potential Impact on Coronary Heart Disease Mortality. Canadian Journal of Cardiology, 2011, 27, 756-762.	1.7	12
210	Another Look at the Human Papillomavirus Vaccine Experience in Canada. American Journal of Public Health, 2011, 101, 1850-1857.	2.7	6
211	Androgen deprivation therapy in prostate cancer: are rising concerns leading to falling use?. BJU International, 2011, 108, 1588-1596.	2.5	25
212	Cost effectiveness of screening immigrants for hepatitis B. Liver International, 2011, 31, 1179-1190.	3.9	47
213	Support surfaces for intraoperative prevention of pressure ulcers in patients undergoing surgery: A cost-effectiveness analysis. Surgery, 2011, 150, 122-132.	1.9	25
214	Early Prevention of Pressure Ulcers Among Elderly Patients Admitted Through Emergency Departments: A Cost-effectiveness Analysis. Annals of Emergency Medicine, 2011, 58, 468-478.e3.	0.6	28
215	Differences and over time changes in levels of prescription opioid analgesic dispensing from retail pharmacies in Canada, 2005-2010. Pharmacoepidemiology and Drug Safety, 2011, 20, 1269-1277.	1.9	72
216	Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: A systematic review. Arthritis Care and Research, 2011, 63, 65-78.	3.4	73

#	ARTICLE	IF	CITATIONS
217	Predicting EQ-5D Utility Scores from the Seattle Angina Questionnaire in Coronary Artery Disease. <i>Medical Decision Making</i> , 2011, 31, 481-493.	2.4	25
218	End-of-Life Care for Lung Cancer Patients in the United States and Ontario. <i>Journal of the National Cancer Institute</i> , 2011, 103, 853-862.	6.3	86
219	Preventing Pressure Ulcers in Long-term Care. <i>Archives of Internal Medicine</i> , 2011, 171, 1839.	3.8	56
220	Coverage with evidence development: The Ontario experience. <i>International Journal of Technology Assessment in Health Care</i> , 2011, 27, 159-168.	0.5	32
221	International drug price comparisons: quality assessment. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2011, 29, 46-51.	1.1	8
222	Health status utilities and the impact of pressure ulcers in long-term care residents in Ontario. <i>Quality of Life Research</i> , 2010, 19, 81-89.	3.1	37
223	Neck pain patients' preference scores for their current health. <i>Quality of Life Research</i> , 2010, 19, 687-700.	3.1	5
224	Evaluating the ability to detect change of health-related quality of life in children with Hodgkin disease. <i>Cancer</i> , 2010, 116, 1608-1614.	4.1	29
225	Sex or survival. <i>Cancer</i> , 2010, 116, 1909-1917.	4.1	21
226	Levels of sex hormones have limited effect on cognition in older men with or without prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 73, 167-175.	4.4	19
227	Cost-Effectiveness of Specialized Multidisciplinary Heart Failure Clinics in Ontario, Canada. <i>Value in Health</i> , 2010, 13, 915-921.	0.3	55
228	Healthcare costs associated with prostate cancer: estimates from a population-based study. <i>BJU International</i> , 2010, 105, 338-346.	2.5	91
229	Health Care Costs Associated with Hepatitis C: A Longitudinal Cohort Study. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2010, 24, 717-726.	1.7	50
230	Impact of Androgen-Deprivation Therapy on Physical Function and Quality of Life in Men With Nonmetastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 5038-5045.	1.6	157
231	Impact of Androgen-Deprivation Therapy on Cognitive Function in Men With Nonmetastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 5030-5037.	1.6	103
232	Association of Temporal Trends in Risk Factors and Treatment Uptake With Coronary Heart Disease Mortality, 1994-2005. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1841.	7.4	253
233	Economic Appraisal of Ontario's Universal Influenza Immunization Program: A Cost-Utility Analysis. <i>PLoS Medicine</i> , 2010, 7, e1000256.	8.4	71
234	Tenofovir and Entecavir Are the Most Effective Antiviral Agents for Chronic Hepatitis B: A Systematic Review and Bayesian Meta-analyses. <i>Gastroenterology</i> , 2010, 139, 1218-1229.e5.	1.3	227

#	ARTICLE	IF	CITATIONS
235	The natural history of hepatitis C infection acquired through injection drug use: Meta-analysis and meta-regression. <i>Journal of Hepatology</i> , 2010, 53, 245-251.	3.7	40
236	Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience. <i>Vaccine</i> , 2010, 28, 6210-6220.	3.8	46
237	“New” Evidence for Clinical Practice Guidelines. <i>Patient</i> , 2010, 3, 71-77.	2.7	7
238	Feasibility of Internet-Based Health-Related Quality of Life Data Collection in a Large Patient Cohort. <i>Journal of Medical Internet Research</i> , 2010, 12, e35.	4.3	18
239	Compulsory school-entry vaccination laws and exemptions: who is opting out in ontario and why does it matter?. <i>Healthcare Policy</i> , 2010, 5, 37-46.	0.6	3
240	Sustained Responders Have Better Quality of Life and Productivity Compared With Treatment Failures Long After Antiviral Therapy for Hepatitis C. <i>American Journal of Gastroenterology</i> , 2009, 104, 2439-2448.	0.4	78
241	Modelling mitigation strategies for pandemic (H1N1) 2009. <i>Cmaj</i> , 2009, 181, 673-680.	2.0	94
242	Utility and health-related quality of life in prostate cancer patients 12 months after radical prostatectomy or radiation therapy. <i>Prostate Cancer and Prostatic Diseases</i> , 2009, 12, 361-368.	3.9	33
243	Lack of Comprehension of Common Prostate Cancer Terms in an Underserved Population. <i>Journal of Clinical Oncology</i> , 2009, 27, 2015-2021.	1.6	69
244	Measuring prostate-specific quality of life in prostate cancer patients scheduled for radiotherapy or radical prostatectomy and reference men in Germany and Canada using the Patient Oriented Prostate Utility Scale-Psychometric (PORPUS-P). <i>BMC Cancer</i> , 2009, 9, 295.	2.6	14
245	How Well Do Guidelines Incorporate Evidence on Patient Preferences?. <i>Journal of General Internal Medicine</i> , 2009, 24, 977-982.	2.6	69
246	Treatment of hepatitis C infection for current or former substance abusers in a community setting. <i>Journal of Viral Hepatitis</i> , 2009, 16, 557-567.	2.0	20
247	Prognosis of hepatitis C virus-infected Canadian post-transfusion compensation claimant cohort. <i>Journal of Viral Hepatitis</i> , 2009, 16, 802-813.	2.0	15
248	Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer. <i>BJU International</i> , 2009, 103, 753-757.	2.5	42
249	Does cirrhosis affect quality of life in hepatitis C virus-infected patients?. <i>Liver International</i> , 2009, 29, 449-458.	3.9	27
250	Identifying the Best Treatment Among Common Nonsurgical Neck Pain Treatments. <i>Journal of Manipulative and Physiological Therapeutics</i> , 2009, 32, S209-S218.	0.9	7
251	Health technology assessment: A comprehensive framework for evidence-based recommendations in Ontario. <i>International Journal of Technology Assessment in Health Care</i> , 2009, 25, 141-150.	0.5	60
252	Acute Appendicitis in Young Children: Cost-effectiveness of US versus CT in Diagnosis—A Markov Decision Analytic Model. <i>Radiology</i> , 2009, 250, 378-386.	7.3	149

#	ARTICLE	IF	CITATIONS
253	Health-state utilities in a prisoner population: a cross-sectional survey. <i>Health and Quality of Life Outcomes</i> , 2009, 7, 78.	2.4	8
254	Is a Mass Immunization Program for Pandemic (H1N1) 2009 Good Value for Money? Early Evidence from the Canadian Experience.. <i>PLOS Currents</i> , 2009, 1, RRN1137.	1.4	4
255	Cost-Effectiveness of Filgrastim and Pegfilgrastim as Primary Prophylaxis against Febrile Neutropenia in Lymphoma Patients Receiving R-CHOP Chemotherapy.. <i>Blood</i> , 2009, 114, 2475-2475.	1.4	1
256	Identifying the Best Treatment Among Common Nonsurgical Neck Pain Treatments. <i>European Spine Journal</i> , 2008, 17, 184-191.	2.2	1
257	Is there an optimal comorbidity index for prostate cancer?. <i>Cancer</i> , 2008, 112, 1043-1050.	4.1	50
258	Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression. <i>Hepatology</i> , 2008, 48, 418-431.	7.3	714
259	Prevalence and predictors of obesity among individuals with positive hepatitis C antibody in a tertiary referral clinic. <i>Journal of Hepatology</i> , 2008, 49, 711-717.	3.7	26
260	The Half-Cycle Correction Explained: Two Alternative Pedagogical Approaches. <i>Medical Decision Making</i> , 2008, 28, 706-712.	2.4	77
261	PCN54 A COST-UTILITY ANALYSIS OF PRIMARY PROPHYLAXIS VERSUS SECONDARY PROPHYLAXIS WITH COLONY-STIMULATING FACTOR IN ELDERLY PATIENTS WITH DIFFUSE AGGRESSIVE LYMPHOMA RECEIVING CURATIVE-INTENT CHEMOTHERAPY USING ONTARIO HEALTH ECONOMIC DATA. <i>Value in Health</i> , 2008, 11, A70-A71.	0.3	0
262	PIN2 A SYSTEMATIC REVIEW OF THE EFFECTIVENESS OF PEGYLATED INTERFERON, LAMIVUDINE, ADEFOVIR AND ENTECAVIR FORTHE TREATMENT OF HEPATITIS B. <i>Value in Health</i> , 2008, 11, A92-A93.	0.3	0
263	PIN43 NATURAL HISTORY OF CHRONIC HCV INFECTION OBTAINED THROUGH INJECTION DRUG USE: A BAYESIAN META-ANALYSIS. <i>Value in Health</i> , 2008, 11, A105-A106.	0.3	0
264	Cost-Effectiveness Analyses of Hepatitis A Vaccine. <i>Pharmacoeconomics</i> , 2008, 26, 17-32.	3.3	57
265	Concordance of Couples™ Prostate Cancer Screening Recommendations from a Decision Analysis. <i>Patient</i> , 2008, 1, 11-19.	2.7	6
266	The Next Step in Guideline Development. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 436.	7.4	223
267	Incorporating Patient Preferences in Evidence-Based Medicine—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 2483.	7.4	42
268	Economics of preventing premature mortality and impaired cognitive development in children through home-fortification: A health policy perspective. <i>International Journal of Technology Assessment in Health Care</i> , 2008, 24, 303-311.	0.5	8
269	Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. <i>Aids</i> , 2008, 22, 1979-1991.	2.2	348
270	Identifying the Best Treatment Among Common Nonsurgical Neck Pain Treatments. <i>Spine</i> , 2008, 33, S184-S191.	2.0	26

#	ARTICLE	IF	CITATIONS
271	A Review and Meta-Analysis of Prostate Cancer Utilities. <i>Medical Decision Making</i> , 2007, 27, 288-298.	2.4	90
272	Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy. <i>American Heart Journal</i> , 2007, 154, 899-907.	2.7	25
273	Management of Solitary 1â€‰cm to 2â€‰cm Liver Nodules in Patients with Compensated Cirrhosis: A Decision Analysis. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2007, 21, 491-500.	1.7	22
274	Cognitive function, mood and health-related quality of life in hepatitis C virus (HCV)-monoinfected and HIV/HCV-coinfected individuals commencing HCV treatment. <i>HIV Medicine</i> , 2007, 8, 192-202.	2.2	36
275	Improved cognitive function as a consequence of hepatitis C virus treatment[*]. <i>HIV Medicine</i> , 2007, 8, 520-528.	2.2	55
276	Responsiveness of disease-specific and generic utility instruments in prostate cancer patients. <i>Quality of Life Research</i> , 2007, 16, 509-522.	3.1	77
277	Marker states and a health state prompt provide modest improvements in the reliability and validity of the standard gamble and rating scale in prostate cancer patients. <i>Quality of Life Research</i> , 2007, 16, 1665-1675.	3.1	9
278	Prostate Cancers Scored as Gleason 6 on Prostate Biopsy are Frequently Gleason 7 Tumors at Radical Prostatectomy: Implication on Outcome. <i>Journal of Urology</i> , 2006, 176, 979-984.	0.4	132
279	Twenty-year secular changes in sex specific lung cancer incidence rates in an urban Chinese population. <i>Lung Cancer</i> , 2006, 51, 13-19.	2.0	25
280	An unadjusted NNT was a moderately good predictor of health benefit. <i>Journal of Clinical Epidemiology</i> , 2006, 59, 224-233.	5.0	24
281	Rethinking 30-day mortality risk after radical prostatectomy. <i>Urology</i> , 2006, 68, 1057-1060.	1.0	18
282	Predictors of Antiviral Therapy in a Post-Transfusion Cohort of Hepatitis C Patients. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2006, 20, 107-111.	1.7	13
283	The Role of the Ossific Nucleus in the Treatment of Established Hip Dislocation. <i>Clinical Orthopaedics and Related Research</i> , 2006, 449, 295-302.	1.5	7
284	The SARS outbreak in a general hospital in Tianjin, China â€” the case of super-spreader. <i>Epidemiology and Infection</i> , 2006, 134, 786-791.	2.1	39
285	Cohort effects in dynamic models and their impact on vaccination programmes: an example from Hepatitis A. <i>BMC Infectious Diseases</i> , 2006, 6, 174.	2.9	17
286	Utility-based Quality of Life Measures in Alzheimerâ€™s Disease. <i>Quality of Life Research</i> , 2006, 15, 631-643.	3.1	103
287	The Effect of Hepatitis C Virus Infection on Health-Related Quality of Life in Prisoners. <i>Journal of Urban Health</i> , 2006, 83, 275-288.	3.6	26
288	A review of interventions triggered by hepatitis A infected food-handlers in Canada. <i>BMC Health Services Research</i> , 2006, 6, 157.	2.2	25

#	ARTICLE	IF	CITATIONS
289	RESPONSE: Re: 30-Day Mortality and Major Complications after Radical Prostatectomy: Influence of Age and Comorbidity. Journal of the National Cancer Institute, 2006, 98, 421-422.	6.3	0
290	Prescribing patterns for Alzheimer disease: survey of Canadian family physicians. Canadian Family Physician, 2006, 52, 208-9.	0.4	11
291	Decision analysis in aerospace medicine: costs and benefits of a hyperbaric facility in space. Aviation, Space, and Environmental Medicine, 2006, 77, 434-42; discussion 442-3.	0.5	0
292	Review: ribavirin is not better than placebo in chronic hepatitis C infection. ACP Journal Club, 2006, 145, 47.	0.1	1
293	Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology) Tj ETQq1 1 0.784314 rgB34Overlock	0.784314	34
294	Vaccines in the public eye. Nature Medicine, 2005, 11, S20-S24.	30.7	29
295	Cost comparison of genetic and clinical screening in families with hereditary hemorrhagic telangiectasia. American Journal of Medical Genetics, Part A, 2005, 137A, 153-160.	1.2	16
296	30-Day Mortality and Major Complications after Radical Prostatectomy: Influence of Age and Comorbidity. Journal of the National Cancer Institute, 2005, 97, 1525-1532.	6.3	172
297	Estimation of Utilities for Chronic Hepatitis C from SF-36 Scores. American Journal of Gastroenterology, 2005, 100, 643-651.	0.4	72
298	Reliability and validity of the PORPUS, a combined psychometric and utility-based quality-of-life instrument for prostate cancer. Journal of Clinical Epidemiology, 2005, 58, 466-474.	5.0	41
299	Potential cost-effectiveness of a preventive hepatitis C vaccine in high risk and average risk populations in Canada. Vaccine, 2005, 23, 1549-1558.	3.8	33
300	PedsQL, and EuroQol Most Responsive Measures To Change in Health-Related Quality of Life in Children with Hodgkin's Disease. Blood, 2005, 106, 1320-1320.	1.4	0
301	Estimating the Prognosis of Hepatitis C Patients Infected by Transfusion in Canada between 1986 and 1990. Medical Decision Making, 2004, 24, 20-29.	2.4	45
302	The association between patient age and prostate cancer stage and grade at diagnosis. BJU International, 2004, 94, 303-306.	2.5	24
303	The effect of English language proficiency on length of stay and in-hospital mortality. Journal of General Internal Medicine, 2004, 19, 221-228.	2.6	251
304	Preferences of husbands and wives for outcomes of prostate cancer screening and treatment. Journal of General Internal Medicine, 2004, 19, 339-348.	2.6	54
305	Azathioprine or Ileocolic Resection for Steroid-Dependent Terminal Ileal Crohn's Disease? A Markov Analysis. Diseases of the Colon and Rectum, 2004, 47, 2120-2130.	1.3	16
306	Improving the accuracy of long-term prognostic estimates in hepatitis C virus infection. Journal of Viral Hepatitis, 2004, 11, 166-174.	2.0	38

#	ARTICLE	IF	CITATIONS
307	Is there age bias in the treatment of localized prostate carcinoma?. <i>Cancer</i> , 2004, 100, 72-81.	4.1	94
308	Quality of life in early Parkinson's disease: Impact of dyskinesias and motor fluctuations. <i>Movement Disorders</i> , 2004, 19, 22-28.	3.9	89
309	The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2003, 49, 283-292.	6.7	87
310	A Canadian national survey of attitudes and knowledge regarding preventive vaccines. <i>Journal of Immune Based Therapies and Vaccines</i> , 2003, 1, 3.	2.4	45
311	Continued undertreatment of older men with localized prostate cancer. <i>Urology</i> , 2003, 62, 860-865.	1.0	83
312	The Cost Effectiveness of ACE Inhibitors as First-Line Antihypertensive Therapy. <i>Pharmacoeconomics</i> , 2003, 21, 573-585.	3.3	15
313	Health-State Utilities and Quality of Life in Hepatitis C Patients. <i>American Journal of Gastroenterology</i> , 2003, 98, 630-638.	0.4	243
314	Do Older Men Benefit From Curative Therapy of Localized Prostate Cancer?. <i>Journal of Clinical Oncology</i> , 2003, 21, 3318-3327.	1.6	157
315	Kidney Transplantation in the Elderly. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 187-196.	6.1	120
316	Patient and Community Preferences for Outcomes in Prostate Cancer. <i>Medical Care</i> , 2003, 41, 153-164.	2.4	113
317	Economic Issues in the Use of Office Spirometry for Lung Health Assessment. <i>Canadian Respiratory Journal</i> , 2003, 10, 320-326.	1.6	10
318	Indications for Interferon/Ribavirin Therapy in Hepatitis C Patients: Findings from a Survey of Canadian Hepatologists. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2003, 17, 183-186.	1.7	10
319	Delay in surgical therapy for clinically localized prostate cancer and biochemical recurrence after radical prostatectomy. <i>Canadian Journal of Urology</i> , 2003, 10, 1891-8.	0.0	50
320	The ten-year rule revisited: accuracy of clinicians' estimates of life expectancy in patients with localized prostate cancer. <i>Urology</i> , 2002, 60, 258-263.	1.0	67
321	Content validity for dementia of three generic preference based health related quality of life instruments. <i>Quality of Life Research</i> , 2002, 11, 71-79.	3.1	55
322	Factors associated with the high cost of liver transplantation in adults. <i>Canadian Journal of Surgery</i> , 2002, 45, 425-34.	1.2	48
323	Initial Bone Marrow Aspiration in Childhood Idiopathic Thrombocytopenia: Decision Analysis. <i>The American Journal of Pediatric Hematology/oncology</i> , 2001, 23, 511-518.	1.3	26
324	Predicting preterm birth: A cost-effectiveness analysis. <i>American Journal of Obstetrics and Gynecology</i> , 2000, 182, 1589-1598.	1.3	44

#	ARTICLE	IF	CITATIONS
325	Construction of the Patient-Oriented Prostate Utility Scale (PORPUS). <i>Journal of Clinical Epidemiology</i> , 2000, 53, 920-930.	5.0	85
326	PROSTATE SPECIFIC ANTIGEN RESPONSE TO MITOXANTRONE AND PREDNISONE IN PATIENTS WITH REFRACTORY PROSTATE CANCER: PROGNOSTIC FACTORS AND GENERALIZABILITY OF A MULTICENTER TRIAL TO CLINICAL PRACTICE. <i>Journal of Urology</i> , 2000, 163, 1481-1485.	0.4	37
327	SIGNIFICANCE OF THE CAG REPEAT POLYMORPHISM OF THE ANDROGEN RECEPTOR GENE IN PROSTATE CANCER PROGRESSION. <i>Journal of Urology</i> , 2000, , 567-572.	0.4	1
328	PROSTATE SPECIFIC ANTIGEN RESPONSE TO MITOXANTRONE AND PREDNISONE IN PATIENTS WITH REFRACTORY PROSTATE CANCER:. <i>Journal of Urology</i> , 2000, , 1481-1485.	0.4	1
329	Principles of Economic Evaluation in Surgery. <i>World Journal of Surgery</i> , 1999, 23, 1242-1248.	1.6	20
330	Review: Plasma-derived hepatitis B vaccine is safe and effective for health care workers. <i>ACP Journal Club</i> , 1998, 128, 45.	0.1	0
331	Guidelines for Verbal Presentations of Medical Decision Analyses. <i>Medical Decision Making</i> , 1997, 17, 228-230.	2.4	8
332	Primer on Medical Decision Analysis: Part 2â€”Building a Tree. <i>Medical Decision Making</i> , 1997, 17, 126-135.	2.4	225
333	Primer on Medical Decision Analysis: Part 4-Analyzing the Model and Interpreting the Results. <i>Medical Decision Making</i> , 1997, 17, 142-151.	2.4	157
334	Primer on Medical Decision Analysis: Part 5â€”Working with Markov Processes. <i>Medical Decision Making</i> , 1997, 17, 152-159.	2.4	209
335	Primer on Medical Decision Analysis: Part 3â€”Estimating Probabilities and Utilities. <i>Medical Decision Making</i> , 1997, 17, 136-141.	2.4	207
336	Primer on Medical Decision Analysis: Part 1â€”Getting Started. <i>Medical Decision Making</i> , 1997, 17, 123-125.	2.4	215
337	Simvastatin was cost-effective in lowering cholesterol in coronary heart disease. <i>ACP Journal Club</i> , 1997, 127, 21.	0.1	0
338	Prevention of hepatitis B virus transmission by immunization: An economic analysis of current recommendations. <i>Journal of Pediatrics</i> , 1996, 128, 715-716.	1.8	0
339	Principles of economic evaluation in cancer screening. <i>Cancer Treatment and Research</i> , 1996, 86, 25-40.	0.5	2
340	Cost-effectiveness analysis: are the outputs worth the inputs?. <i>ACP Journal Club</i> , 1996, 124, 82.	0.1	10
341	Screening for Prostate Cancer-Reply. <i>JAMA - Journal of the American Medical Association</i> , 1995, 273, 1175.	7.4	0
342	Issues in the Cost-Effectiveness of Asthma Education. <i>Chest</i> , 1994, 106, 264S-269S.	0.8	16

#	ARTICLE	IF	CITATIONS
343	Screening for Prostate Cancer. JAMA - Journal of the American Medical Association, 1994, 272, 773.	7.4	186
344	Review: Alpha-interferon terminates viral replications and eradicates the carrier state in chronic hepatitis B virus infection. ACP Journal Club, 1994, 120, 12.	0.1	1
345	Should Canada and the United States Universally Vaccinate Infants against Hepatitis B?. Medical Decision Making, 1993, 13, 4-20.	2.4	71
346	Discounting in the Economic Evaluation of Health Care Interventions. Medical Care, 1993, 31, 403-418.	2.4	165
347	Screening newborns plus universal vaccination of 10-year olds was the most cost effective hepatitis B vaccination strategy. ACP Journal Club, 1993, 118, 93.	0.1	0
348	Comparison of an Aggressive (U.S.) and a Less Aggressive (Canadian) Policy for Cholesterol Screening and Treatment. Annals of Internal Medicine, 1991, 115, 248-255.	3.9	35
349	Pravastatin reduced total and LDL cholesterol more than gemfibrozil in primary hypercholesterolemia. ACP Journal Club, 1991, 114, 77.	0.1	0